You can't control the headlines—but it doesn't hurt to try. That seems to be the lesson from Merck & Co. Inc.'s handling of the latest potential setback to its ezetimibe-based cholesterol franchise ( Zetia/Vytorin).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?